These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1863402)

  • 1. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.
    Montefiori DC; Lefkowitz LB; Keller RE; Holmberg V; Sandstrom E; Phair JP
    AIDS; 1991 May; 5(5):513-7. PubMed ID: 1863402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease.
    Füst G; Tóth FD; Kiss J; Ujhelyi E; Nagy I; Bánhegyi D
    AIDS; 1994 May; 8(5):603-9. PubMed ID: 7914732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection.
    Tóth FD; Szabó B; Ujhelyi E; Pálóczi K; Horváth A; Füst G; Kiss J; Bánhegyi D; Hollán SR
    AIDS; 1991 Mar; 5(3):263-8. PubMed ID: 1676275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement-mediated, antibody-dependent neutralizing titers of sera from asymptomatic and symptomatic HIV-infected individuals.
    Spear GT; Carlson JR; Jennings MB; Takefman DM; Landay AL
    AIDS; 1992 Sep; 6(9):1047. PubMed ID: 1388899
    [No Abstract]   [Full Text] [Related]  

  • 5. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.
    Willey S; Aasa-Chapman MM; O'Farrell S; Pellegrino P; Williams I; Weiss RA; Neil SJ
    Retrovirology; 2011 Mar; 8():16. PubMed ID: 21401915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
    Zhou J; Montefiori DC
    Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of antibodies that are associated with disease progression in HIV disease.
    Tóth FD; Süsal C; Ujhelyi E; Bánhegyi D; Kiss J; Daniel V; Nagy I; Opelz G; Füst G
    Immunol Lett; 1994 Jun; 41(1):33-6. PubMed ID: 7959901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.
    Broliden K; Sievers E; Tovo PA; Moschese V; Scarlatti G; Broliden PA; Fundaro C; Rossi P
    Clin Exp Immunol; 1993 Jul; 93(1):56-64. PubMed ID: 8324904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.
    Lund O; Hansen J; Søorensen AM; Mosekilde E; Nielsen JO; Hansen JE
    J Virol; 1995 Apr; 69(4):2393-400. PubMed ID: 7884885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.
    Homsy J; Meyer M; Levy JA
    J Virol; 1990 Apr; 64(4):1437-40. PubMed ID: 2319642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
    Nkengasong JN; Peeters M; Ndumbe P; Janssens W; Willems B; Fransen K; Ngolle M; Piot P; van der Groen G
    AIDS; 1994 Aug; 8(8):1089-96. PubMed ID: 7986404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 14. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients.
    Wilfingseder D; Spruth M; Ammann CG; Döpper S; Speth C; Dierich MP; Stoiber H
    Int Arch Allergy Immunol; 2003 May; 131(1):62-72. PubMed ID: 12759492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.
    Björling E; Scarlatti G; von Gegerfelt A; Albert J; Biberfeld G; Chiodi F; Norrby E; Fenyö EM
    Virology; 1993 Mar; 193(1):528-30. PubMed ID: 8438591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART).
    Bánhegyi D; Bácsi A; Tóth FD; Prohászka Z; Horváth A; Beck Z; Kónya J; Füst G
    Immunol Lett; 2003 Oct; 89(1):25-30. PubMed ID: 12946861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.
    Haubrich RH; Takeda A; Koff W; Smith G; Ennis FA
    J Infect Dis; 1992 Mar; 165(3):545-8. PubMed ID: 1538159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
    Posner MR; Elboim HS; Cannon T; Cavacini L; Hideshima T
    AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.